Design, Synthesis and Biological Evaluation of Novel Piperazinone Derivatives as Cytotoxic Agents.
Ghasemi S, Sharifi S, Shahbazi Mojarrad J.
Adv Pharm Bull · research-article; journal article · DOI 10.34172/apb.2020.051 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för L-778,123 hydrochloride. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
15 träffarK-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V, Mahapatra DK, Bharti SK.
Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2016.09.049Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines.
Ghasemi S, Davaran S, Sharifi S, Asgari D, Abdollahi A, Shahbazi Mojarrad J.
Adv Pharm Bull · research-article; journal article · DOI 10.5681/apb.2013.012Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Morgan MA, Onono FO, Spielmann HP, Subramanian T, Scherr M, Venturini L, Dallmann I, Ganser A, Reuter CW.
J Mol Med (Berl) · research support, non-u.s. gov't; journal article · DOI 10.1007/s00109-011-0814-7ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly R, Vallis KA.
J Nucl Med · research support, non-u.s. gov't; journal article · DOI 10.2967/jnumed.110.084392A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting.
Onono FO, Morgan MA, Spielmann HP, Andres DA, Subramanian T, Ganser A, Reuter CW.
Mol Cell Proteomics · research support, non-u.s. gov't; research-article; evaluation study; journal article; research support, n.i.h., extramural · DOI 10.1074/mcp.m900597-mcp200Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123.
Si MS, Reitz BA, Borie DC.
Invest New Drugs · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1023/b:drug.0000047102.26698.08A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM.
Clin Cancer Res · clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-04-0248Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes.
Reid TS, Long SB, Beese LS.
Biochemistry · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1021/bi049280bFarnesyl transferase inhibitors for patients with lung cancer.
Johnson BE, Heymach JV.
Clin Cancer Res · review; journal article · DOI 10.1158/1078-0432.ccr-040016The effects of the farnesyl transferase inhibitor FTI L-778,123 on normal, myelodysplastic, and myeloid leukemia bone marrow progenitor proliferation in vitro.
Huang XK, Meyer P, Li B, Raza A, Preisler HD.
Leuk Lymphoma · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1080/1042819021000040387Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, Abbruzzese JL, Fuchs CS, Rowinsky EK, Rubin EH, Sharma S, Deutsch PJ, Mazina KE, Morrison BW, Wildonger L, Yao SL, Kohl NE.
Mol Cancer Ther · journal articleA Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
Hahn SM, Bernhard EJ, Regine W, Mohiuddin M, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, DeLaney TF, Kiel KD, Morrison B, Deutsch P, Muschel RJ, McKenna WG.
Clin Cancer Res · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal articleA phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S, Spriggs D.
Clin Cancer Res · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal articleHigh-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.
Buser CA, Dinsmore CJ, Fernandes C, Greenberg I, Hamilton K, Mosser SD, Walsh ES, Williams TM, Koblan KS.
Anal Biochem · journal article · DOI 10.1006/abio.2000.4972